Glucagon radioimmunoassay with use of antiserum to glucagon C-terminal fragment.
Tatsuya Nishino, Tsukasa Kodaira, Seok-Hwan Shin, K Imagawa, Kenji Shima, Y Kumahara, Chizuko Yanaihara, N Yanaihara
Abstract
Tatsuya Nishino, Tsukasa Kodaira, Seok-Hwan Shin, K Imagawa, Kenji Shima, Y Kumahara, Chizuko Yanaihara, N Yanaihara
Abstract
In this pancreatic-glucagon-specific radioimmunoassay we used C-terminal-region-specific antiserum. OAL-123, produced against a 19-29 C-terminal fragment of porcine glucagon. On measurement of pooled plasma the ranges for intra- and inter-assay coefficients of variation were 4.8-8.1% and 7.5-10.7%, respectively. The concentration of immunoreactive glucagon in plasma of healthy subjects, as measured with the OAL-123 assay system, was 87.9 (SD 23.8) ng/L. Measurement of the same plasma samples with the 30K assay system (30K being an antiserum highly specific for pancreatic glucagon) showed a comparable value, 86.2 (SD 26.3) ng/L. We followed changes in human and dog plasma immunoreactive glucagon concentrations on arginine infusion and after glucose load, using the OAL-123 and the 30K assay systems, with identical results. Combining other results of comparative immunochemical characterization of the OAL-123 and 30K assay systems, we confirmed that the antisera raised against the C-terminal fragment of glucagon can be used in radioimmunoassay of pancreatic glucagon.
OpenAlex reports 101 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
In this pancreatic-glucagon-specific radioimmunoassay we used C-terminal-region-specific antiserum. OAL-123, produced against a 19-29 C-terminal fragment of porcine glucagon. On measurement of pooled plasma the ranges for intra- and inter-assay coefficients of variation were 4.8-8.1% and 7.5-10.7%, respectively. The concentration of immunoreactive glucagon in plasma of healthy subjects, as measured with the OAL-123 assay system, was 87.9 (SD 23.8) ng/L. Measurement of the same plasma samples with the 30K assay system (30K being an antiserum highly specific for pancreatic glucagon) showed a comparable value, 86.2 (SD 26.3) ng/L. We followed changes in human and dog plasma immunoreactive glucagon concentrations on arginine infusion and after glucose load, using the OAL-123 and the 30K assay systems, with identical results. Combining other results of comparative immunochemical characterization of the OAL-123 and 30K assay systems, we confirmed that the antisera raised against the C-terminal fragment of glucagon can be used in radioimmunoassay of pancreatic glucagon.
Key concepts: Glucagon, Radioimmunoassay, Antiserum, Internal medicine, Endocrinology, Arginine, Chemistry, Antibody